ArticleJournal of hand surgery global online2026
Likelihood of Dupuytren Contracture Recurrence After Limited Fasciectomy, Needle Aponeurotomy or Collagenase
Article in Journal of hand surgery global online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Compare contracture recurrence after limited fasciectomy (LF), collagenase Methods: Systematic review restricted to prospective cohort series or randomized controlled trials treating DC with LF, CCH, and/or NA. Eligibility required ≥2-year, in-person clinical follow-up and explicit definition of contracture recurrence. Exclusions included non-English publications, telephone/questionnaire-only follow-up, no recurrence data at follow-up, and sample size <15 patients. The primary end point was recurrence by treatment. Secondary analyses evaluated recurrence by joint treated and reintervention and complications when reported. Results: Ten studies met criteria, encompassing 1,411 patients and 1,698 treated joints with a mean follow-up of 3.8 years. Across studies, LF demonstrated a lower risk of recurrence than both CCH and NA, and CCH demonstrated a lower risk of recurrence than NA. Recurrence was less likely in the treatment of MCP versus PIP contractures across all treatments. For studies that reported subsequent procedures for recurrence, there was a lower likelihood of reinterventions after LF than after CCH or NA. Commonly reported complications included digital nerve injury, tendon injury, skin tears, swelling, pain, and bleeding. Conclusions: In prospectively collected cohorts with a mean 3.8 years of follow-up, recurrence after DC treatment was common. LF demonstrated the lowest recurrence (16.5%), CCH had an intermediate recurrence (32.5%), and NA showed the highest recurrence (46.4%). PIP joint contractures were more likely to recur than MCP joint contractures, regardless of treatment. Clinical relevance: LF offers greater durability and a lower likelihood of subsequent procedures than CCH or NA in the treatment of DC at intermediate term follow-up; however, the clinician must also weigh the length of recovery and potential complications between these three treatment options. Patients with PIP contractures should be counseled about a higher recurrence risk and potential need for closer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.